Johan Bosmans1, Sabine Bleiziffer2, Ulrich Gerckens3, Peter Wenaweser4, Stephen Brecker5, Corrado Tamburino6, Axel Linke7. 1. Antwerp University Hospital, Edegem, Belgium. Electronic address: johan.bosmans@uza.be. 2. German Heart Center, Technical University Munich, Munich, Germany. 3. Gemeinschaftskrankenhaus, Bonn, Germany. 4. Bern University Hospital, Bern, Switzerland. 5. St. George's Hospital, London, United Kingdom. 6. Ferrarotto Hospital, University of Catania, Catania, Italy. 7. University of Leipzig Heart Center, Leipzig, Germany.
Abstract
BACKGROUND: Transcatheter aortic valve replacement (TAVR) enables treatment of high-risk patients with symptomatic aortic stenosis without open-heart surgery; however, the benefits are mitigated by the potential for neurological events. OBJECTIVES: This study sought to determine the timing and causes of clinically relevant neurological events after self-expandable TAVR. METHODS: We enrolled 1,015 patients, of whom 996 underwent TAVR with a self-expandable system at 44 TAVR-experienced centers in Europe, Colombia, and Israel. Neurological events were evaluated for 3 distinct time periods: periprocedural (0 to 1 days post TAVR); early (2 to 30 days); and late (31 to 730 days). In this real-world study, neurological events were first referred to the site neurologist and then reviewed by an independent neurologist. RESULTS: The overall stroke rate was 1.4% through the first day post-procedure, 3.0% at 30 days, and 5.6% at 2 years. There were no significant predictors of periprocedural stroke or stroke/transient ischemic attack (TIA) combined. Significant predictors of early stroke were acute kidney injury (p = 0.03), major vascular complication (p = 0.04), and female sex (p = 0.04). For stroke/TIA combined, prior atrial fibrillation (p = 0.03) and major vascular complication (p = 0.009) were predictive. Coronary artery bypass graft surgery was the only significant predictor of late stroke (p = 0.007) or late stroke/TIA (p = 0.06). CONCLUSIONS: Treatment of high-risk patients with aortic stenosis using a self-expandable system was associated with a low stroke rate at short- and long-term follow-up. Multivariable predictors of clinically relevant neurological events differed on the basis of the timing after TAVR. (CoreValve Advance International Post Market Study; NCT01074658).
BACKGROUND: Transcatheter aortic valve replacement (TAVR) enables treatment of high-risk patients with symptomatic aortic stenosis without open-heart surgery; however, the benefits are mitigated by the potential for neurological events. OBJECTIVES: This study sought to determine the timing and causes of clinically relevant neurological events after self-expandable TAVR. METHODS: We enrolled 1,015 patients, of whom 996 underwent TAVR with a self-expandable system at 44 TAVR-experienced centers in Europe, Colombia, and Israel. Neurological events were evaluated for 3 distinct time periods: periprocedural (0 to 1 days post TAVR); early (2 to 30 days); and late (31 to 730 days). In this real-world study, neurological events were first referred to the site neurologist and then reviewed by an independent neurologist. RESULTS: The overall stroke rate was 1.4% through the first day post-procedure, 3.0% at 30 days, and 5.6% at 2 years. There were no significant predictors of periprocedural stroke or stroke/transient ischemic attack (TIA) combined. Significant predictors of early stroke were acute kidney injury (p = 0.03), major vascular complication (p = 0.04), and female sex (p = 0.04). For stroke/TIA combined, prior atrial fibrillation (p = 0.03) and major vascular complication (p = 0.009) were predictive. Coronary artery bypass graft surgery was the only significant predictor of late stroke (p = 0.007) or late stroke/TIA (p = 0.06). CONCLUSIONS: Treatment of high-risk patients with aortic stenosis using a self-expandable system was associated with a low stroke rate at short- and long-term follow-up. Multivariable predictors of clinically relevant neurological events differed on the basis of the timing after TAVR. (CoreValve Advance International Post Market Study; NCT01074658).
Authors: Sabine Bleiziffer; Johan Bosmans; Stephen Brecker; Ulrich Gerckens; Peter Wenaweser; Corrado Tamburino; Axel Linke Journal: Clin Res Cardiol Date: 2017-05-08 Impact factor: 5.460
Authors: Vinod H Thourani; Sean M O'Brien; John J Kelly; David J Cohen; Eric D Peterson; Michael J Mack; David M Shahian; Frederick L Grover; John D Carroll; J Matthew Brennan; Jessica Forcillo; Suzanne V Arnold; Sreekanth Vemulapalli; Susan Fitzgerald; David R Holmes; Joseph E Bavaria; Fred H Edwards Journal: Ann Thorac Surg Date: 2018-12-07 Impact factor: 4.330
Authors: Arash Salemi; Andrea De Micheli; Abdullah Aftab; Adham Elmously; Regis Chang; S Chiu Wong; Berhane M Worku Journal: Interact Cardiovasc Thorac Surg Date: 2018-12-01
Authors: Laura Stein; Alison Thaler; John W Liang; Stanley Tuhrim; Amit S Dhamoon; Mandip S Dhamoon Journal: J Am Heart Assoc Date: 2017-12-02 Impact factor: 5.501